In conclusion, the decreasing levels of CD1d on monocytes may contribute to AML and ALL progression, as a correlation was observed between the levels of CD1d on monocytes and the number/cytotoxicity of CD3+CD56+ T lymphocytes in AML and ALL patients. This evidence concerns the gene CD1D and acute myeloid leukemia.